Wave Life Sciences
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which evaluates WVE-007—an investigational RNA interference (RNAi) therapy targeting the INHBE gene—aims to revolutionize obesity treatment by focusing